IP Library Granted Patent US 10,717,993
Granted Patent B2
US 10,717,993 · App. 15/095,858 · Granted Jul 21, 2020

Methods and compositions for increased transgene expression

Inventors: Michael C. Holmes (Richmond, CA); Gary Ka Leong Lee (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/86C12N5/0636C12N15/63C12N2501/2315C12N2501/51C12N2501/515C12N2510/02C12N2710/10343
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,717,993
App. No.
15/095,858
Granted
Jul 21, 2020
Kind
B2
Abstract

Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies.

Claims (11)

1. A method for expressing an exogenous sequence in CD4+ T-cells said method comprising:

activating a population of the CD4+ T-cells with anti-CD3/anti-CD28 beads;

contacting the CD+4 T-cells with a feeder cell: and

contacting the activated CD4+ T cell population with the feeder cells with one or more adenoviral expression vectors comprising said exogenous sequence and a sequence encoding a zinc finger nuclease, wherein the one or more expression vectors comprise control sequences that drive expression of the exogenous sequence and the zinc finger nuclease;

wherein T cells within the activated T cell population comprising the adenovirus vectors express the exogenous sequence.

2. The method according to claim 1 , wherein the one or more adenoviral expression vectors are pseudotyped.

3. The method according to claim 2 , wherein the one or more pseudotyped adenovirus expression vector comprises sequences from Ad5 and Ad35 adenoviruses.

4. The method according to claim 3 , wherein the Ad35 sequence is F35.

5. The method according to claim 1 , wherein the zinc finger nuclease binds to a target site in a CCR5 gene.

6. The method of claim 1 , wherein the zinc finger nuclease cleaves an endogenous gene.

7. The method of claim 6 , wherein the endogenous gene is a CCR5 gene.

Assignments (1)
CHANGE OF NAME Recorded Apr 8, 2020
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 052350/0939 →
Continuity (10)
Continuation 14223692 · Mar 24, 2014
Continuation In Part 14054042 · Oct 15, 2013
Continuation 13068348 · May 9, 2011
Continuation 12154439 · May 22, 2008
Continuation 11805707 · May 23, 2007
Provisional Application 60939825 · May 23, 2007
Provisional Application 60926911 · Apr 30, 2007
Provisional Application 60847269 · Sep 26, 2006
Provisional Application 60808501 · May 25, 2006
Related Publication 20160215298A1 · Jul 28, 2016